2011
DOI: 10.1055/s-0031-1281587
|View full text |Cite
|
Sign up to set email alerts
|

Neue Entwicklungen zur Genetik und Therapie des Retinoblastoms

Abstract: Retinoblastomas are the most frequent primary malignant intraocular tumours worldwide. Conventional and new treatment modalities have significantly improved the chance for survival and preservation of vision. The armamentarium of treatment modalities has been broadened recently by new techniques like intraarterial chemotherapy, which still has to be considered as experimental since long-term follow-up results are not yet available. The excellent prognosis for retinoblastomas in countries with a well developed … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2014
2014
2021
2021

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 18 publications
0
1
0
Order By: Relevance
“…Choice of therapy is based on the International Intraocular Retinoblastoma Classification (IIRC) or the International Classification of Retinoblastoma (ICRB), which divides groups of different tumor expansion. As the most effective treatment option, enucleation remains the therapy of choice for patients with massive disease extent such as high-risk groups D or E according to IIRC and ICRB and in cases of failure of alternative therapies 1 , 5 , 6 , 8 9 10 11 12 13 . In a multicenter study, including 2854 eyes, primary enucleation was performed in 41.3%.…”
Section: Introductionmentioning
confidence: 99%
“…Choice of therapy is based on the International Intraocular Retinoblastoma Classification (IIRC) or the International Classification of Retinoblastoma (ICRB), which divides groups of different tumor expansion. As the most effective treatment option, enucleation remains the therapy of choice for patients with massive disease extent such as high-risk groups D or E according to IIRC and ICRB and in cases of failure of alternative therapies 1 , 5 , 6 , 8 9 10 11 12 13 . In a multicenter study, including 2854 eyes, primary enucleation was performed in 41.3%.…”
Section: Introductionmentioning
confidence: 99%